Florham Park, NJ, July 13, 2021
Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Tobramycin Vial for Injection, 1.2g, generic to Nebcin®.
Annual market sales for Nebcin® and its generics for the twelve month period ending April, 2021 were $16 million, according to IQVIA™.
Xiromed CEO, Narasimhan Mani commented, “Xiromed is focused on expanding our injectable offerings in order to create value for our institutional customers. We are excited for the launch of Tobramycin Vial for Injection to advance our injectable strategy and further grow our injectable portfolio.” Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.
Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/